Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection

Helen C. Stankiewicz Karita, Tracy Q. Dong, Christine Johnston, Kathleen M. Neuzil, Michael K. Paasche-Orlow, Patricia J. Kissinger, View ORCID ProfileAnna Bershteyn, Lorna E. Thorpe, Meagan Deming, Angelica Kottkamp, Miriam Laufer, Raphael J. Landovitz, Alfred Luk, Risa Hoffman, View ORCID ProfilePavitra Roychoudhury, Craig A. Magaret, View ORCID ProfileAlexander L. Grenninger, Meei-Li Huang, Keith R. Jerome, Mark Wener, Connie Celum, Helen Y. Chu, Jared M. Baeten, Anna Wald, Ruanne V. Barnabas, Elizabeth R. Brown, the Hydroxychloroquine COVID-19 PEP Study Team
doi: https://doi.org/10.1101/2021.08.27.21262754
Helen C. Stankiewicz Karita
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: helensk{at}uw.edu
Tracy Q. Dong
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Johnston
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Neuzil
9University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael K. Paasche-Orlow
10Boston University School of Medicine, Boston, MA
11Boston Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia J. Kissinger
12Tulane University, New Orleans, LA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Bershteyn
13New York University Grossman School of Medicine, NY, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Bershteyn
Lorna E. Thorpe
13New York University Grossman School of Medicine, NY, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan Deming
9University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelica Kottkamp
13New York University Grossman School of Medicine, NY, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Laufer
9University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael J. Landovitz
14University of California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Luk
12Tulane University, New Orleans, LA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Risa Hoffman
14University of California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavitra Roychoudhury
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pavitra Roychoudhury
Craig A. Magaret
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander L. Grenninger
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander L. Grenninger
Meei-Li Huang
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith R. Jerome
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Wener
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
3Division of Rheumatology, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Connie Celum
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
4Department of Global Health, University of Washington, Seattle, WA
5Department of Epidemiology, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Y. Chu
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
4Department of Global Health, University of Washington, Seattle, WA
5Department of Epidemiology, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared M. Baeten
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
4Department of Global Health, University of Washington, Seattle, WA
5Department of Epidemiology, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Wald
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
5Department of Epidemiology, University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruanne V. Barnabas
1Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
4Department of Global Health, University of Washington, Seattle, WA
5Department of Epidemiology, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Brown
6Department of Biostatistics University of Washington, Seattle, WA
7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
8Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance SARS-CoV-2 viral trajectory has not been well-characterized in documented incident infections. These data will inform SARS-CoV-2 natural history, transmission dynamics, prevention practices, and therapeutic development.

Objective To prospectively characterize early SARS-CoV-2 viral shedding in persons with incident infection.

Design Prospective cohort study.

Setting Secondary data analysis from a multicenter study in the U.S.

Participants The samples derived from a randomized controlled trial of 829 community-based asymptomatic participants recently exposed (<96 hours) to persons with SARS-CoV-2. Participants collected daily mid-turbinate swabs for SARS-CoV-2 detection by polymerase-chain-reaction and symptom diaries for 14-days. Persons with negative swab for SARS-CoV-2 at baseline who developed infection during the study were included in the analysis.

Exposure Laboratory-confirmed SARS-CoV-2 infection.

Main outcomes and measures The observed SARS-CoV-2 viral shedding characteristics were summarized and shedding trajectories were examined using a piece-wise linear mixed-effects modeling. Whole viral genome sequencing was performed on samples with cycle threshold (Ct)<34.

Results Ninety-seven persons (57% women, median age 37-years) developed incident infections during 14-days of follow-up. Two-hundred fifteen sequenced samples were assigned to 15 lineages that belonged to the G614 variant. Forty-two (43%), 18(19%), and 31(32%) participants had viral shedding for 1 day, 2-6 days, and ≥7 days, with median peak viral load Ct of 38.5, 36.7, and 18.3, respectively. Six (6%) participants had 1–6 days of observed viral shedding with censored duration. The peak average viral load was observed on day 3 of viral shedding. The average Ct value was lower, indicating higher viral load, in persons reporting COVID-19 symptoms than asymptomatic. Using the statistical model, the median time from shedding onset to peak viral load was 1.4 days followed by a median of 9.7 days before clearance.

Conclusions and Relevance Incident SARS-CoV-2 G614 infection resulted in a rapid viral load peak followed by slower decay and positive correlation between peak viral load and shedding duration; duration of shedding was heterogeneous. This longitudinal evaluation of the SARS-CoV-2 G614 variant with frequent molecular testing may serve as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.

Question What are the early SARS-CoV-2 G614 viral shedding characteristics in persons with incident infection?

Findings In this prospective cohort of 97 community-based participants who collected daily mid-turbinate swabs for SARS-CoV-2 detection after recent exposure to SARS-CoV-2, viral trajectory was characterized by a rapid peak followed by slower decay. Peak viral load correlated positively with symptoms. The duration of shedding was heterogeneous.

Meaning A detailed description of the SARS-CoV-2 G614 viral shedding trajectory serves as baseline for comparison to new viral variants of concern and inform models for the planning of clinical trials and transmission dynamics to end this pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Primary funding source: Bill & Melinda Gates Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Western Institutional Review Board approved the trial; all participants provided informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Relevant data are available from the corresponding author on request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 31, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection
Helen C. Stankiewicz Karita, Tracy Q. Dong, Christine Johnston, Kathleen M. Neuzil, Michael K. Paasche-Orlow, Patricia J. Kissinger, Anna Bershteyn, Lorna E. Thorpe, Meagan Deming, Angelica Kottkamp, Miriam Laufer, Raphael J. Landovitz, Alfred Luk, Risa Hoffman, Pavitra Roychoudhury, Craig A. Magaret, Alexander L. Grenninger, Meei-Li Huang, Keith R. Jerome, Mark Wener, Connie Celum, Helen Y. Chu, Jared M. Baeten, Anna Wald, Ruanne V. Barnabas, Elizabeth R. Brown, the Hydroxychloroquine COVID-19 PEP Study Team
medRxiv 2021.08.27.21262754; doi: https://doi.org/10.1101/2021.08.27.21262754
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection
Helen C. Stankiewicz Karita, Tracy Q. Dong, Christine Johnston, Kathleen M. Neuzil, Michael K. Paasche-Orlow, Patricia J. Kissinger, Anna Bershteyn, Lorna E. Thorpe, Meagan Deming, Angelica Kottkamp, Miriam Laufer, Raphael J. Landovitz, Alfred Luk, Risa Hoffman, Pavitra Roychoudhury, Craig A. Magaret, Alexander L. Grenninger, Meei-Li Huang, Keith R. Jerome, Mark Wener, Connie Celum, Helen Y. Chu, Jared M. Baeten, Anna Wald, Ruanne V. Barnabas, Elizabeth R. Brown, the Hydroxychloroquine COVID-19 PEP Study Team
medRxiv 2021.08.27.21262754; doi: https://doi.org/10.1101/2021.08.27.21262754

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (754)
  • Anesthesia (221)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (363)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13352)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5142)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3263)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1016)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4916)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2518)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4201)
  • Public and Global Health (7492)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)